Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
Want to see ATHE full AI Analyst Report?
ATHE Stock Chart & Stats
$3.55
-$0.16(-4.23%)
At close: 4:00 PM EST
$3.55
-$0.16(-4.23%)
Day’s Range― - ―
52-Week Range$2.66 - $7.00
Previous CloseN/A
Volume131.33K
Average Volume (3M)13.05K
Market Cap
$77.65M
Enterprise Value$59.72M
Total Cash (Recent Filing)$49.15M
Total Debt (Recent Filing)$98.35K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding18,125,694
10 Day Avg. Volume16,981
30 Day Avg. Volume13,055
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue15.58
Enterprise Value/Gross Profit16.09
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$12.00Price Target Upside238.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$2.36M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins above 90% indicate highly favorable unit economics and efficient cost structure for current activities. That margin cushion supports future scale-up economics, improving the odds that increased revenue from trials or partnerships can translate into positive operating leverage over time.
Recent Revenue GrowthA 46% recent revenue increase suggests the company is expanding its commercial or partnering traction despite being clinical-stage. Durable top-line growth helps validate demand for the platform, supports scaling plans, and can attract non-dilutive partners or licensing opportunities needed for late-stage development.
Regulatory Progress Toward Phase 3Constructive FDA feedback on CMC and clinical plans and being on track for an End-of-Phase 2 meeting materially reduces development execution risk. Regulatory alignment on manufacturing and trial design strengthens the pathway to a pivotal Phase 3, improving long-term commercialization prospects if efficacy is confirmed.
Bears Say
Persistent UnprofitabilityOngoing net losses and negative EBIT margins show the company is not yet profitable and must rely on external funding. Persistent unprofitability limits reinvestment capacity, increases dilution risk for equity holders, and constrains strategic flexibility during the multi-year drug development cycle.
Negative Operating And Free Cash FlowConsistently negative operating and free cash flows indicate cash burn that will require financing or partnerships to support Phase 3. Reliance on new capital raises or deals introduces execution and dilution risk and can delay trials or commercialization if markets or partners are not available on favorable terms.
Single-asset, Clinical-stage ConcentrationA heavy reliance on a single lead asset in a high-failure area (neurodegeneration/MSA) creates binary outcome risk: pivotal trial or approval failure would severely impair value. Small organizational scale further constrains parallel programs and increases dependency on partners for late-stage execution and commercialization.
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $2.66 and its highest was $7.00 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $77.65M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 283 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 25, 2026. The company reported -$0.383 earnings per share for the quarter, missing the consensus estimate of -$0.231 by -$0.152.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 18,125,694 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.383 in its last earnings report, missing expectations of -$0.231. Following the earnings report the stock price went up 2.945%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (238.03% Upside)
$12.00 (238.03% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.18%
12-Months-Change
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
ATHE Stock 12 Month Forecast
Average Price Target
$12.00
▲(238.03% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.94% Other Institutional Investors
99.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---